Search the Newsreel

Colgate-Palmolive (CL) Stock Could Trade At A Discount After Its 32% Run

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Colgate-Palmolive stock has delivered a 32.3% return over the past three years, yet the current checks send mixed signals on value, with the Discounted Cash …

Colgate-Palmolive (CL) Could Be 30% Undervalued Despite A 6% Overvalued Narrative

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Colgate-Palmolive (CL) recently closed at $91.95 in US$ terms, setting a fresh reference point for investors. The stock's move comes alongside published figures …

Mitsubishi UFJ Trust & Banking Corp Grows Stake in Colgate-Palmolive Company $CL

Mitsubishi UFJ Trust & Banking Corp increased its stake in Colgate-Palmolive Company by 3.5% in the second quarter, now owning over 1 million shares valued at $96.59 million. Other institutional investors also adjusted their positions, and insider selling by CEO Noel R. Wallace and …

Colgate-Palmolive Company $CL Shares Sold by KBC Group NV

KBC Group NV reduced its stake in Colgate-Palmolive Company (NYSE:CL) by 9.1% during the second quarter, selling 27,336 shares. Despite this, many other institutional investors increased their holdings, indicating varied sentiment. The article also details recent insider stock sales by CEO Noel R. Wallace …

Focus Partners Advisor Solutions LLC Purchases Shares of 10,829 Molina Healthcare, Inc $MOH

Focus Partners Advisor Solutions LLC has acquired a new stake of 10,829 shares in Molina Healthcare, Inc. (NYSE:MOH) valued at approximately $2.48 million during the second quarter. This move is part of a broader trend of institutional investors modifying their holdings in Molina Healthcare, …

Colgate-Palmolive Company $CL Shares Sold by HighTower Advisors LLC

HighTower Advisors LLC reduced its stake in Colgate-Palmolive Company (NYSE:CL) by 32.4% during the second quarter, selling 278,102 shares and retaining 579,234 shares worth $53.1 million. Despite this, other institutional investors have increased their positions. The company recently reported strong quarterly earnings, topping analyst …

Why Colgate-Palmolive (CL) Is Getting Attention Again

Colgate-Palmolive (CL) has garnered investor attention after closing at $91.95, following an 18.36% year-to-date share price gain. The company reported strong Q2 net sales growth and an 8% increase in Base Business EPS, extending its earnings beat streak to five quarters. While one valuation …

Molina Healthcare (MOH) Is Up 7.2% After Strong Q1 Results And Clearer Medicaid Funding Outlook

Molina Healthcare (MOH) saw its stock rise by 7.2% following strong first-quarter 2026 results and improved clarity on Medicaid funding. Regulatory updates and increased investor interest, including a larger stake from Michael Burry, have positively impacted its operating outlook. The company's performance is tied …

Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Cuts Target Price to $2

Maxim Group has reiterated its Buy rating for Moleculin Biotech (MBRX.US) but has reduced the target price for the stock to $2. This adjustment reflects a revised outlook on the company's valuation while maintaining a positive long-term perspective.

TD Asset Management Inc Has $306.62 Million Stake in Colgate-Palmolive Company $CL

TD Asset Management Inc. recently reduced its stake in Colgate-Palmolive Company by 6.4% in the second quarter, now holding 3.34 million shares valued at $306.62 million. Despite this, institutional investors collectively own 80.41% of the company. Colgate-Palmolive reported strong quarterly earnings, beating estimates with …

Colgate-Palmolive Company $CL Stock Position Increased by Qsemble Capital Management LP

Qsemble Capital Management LP significantly increased its stake in Colgate-Palmolive Company by 124.9% in the second quarter, now holding 69,862 shares valued at $6.4 million. This move is part of broader institutional interest, with analysts maintaining a "Moderate Buy" rating and an average price …

Massachusetts Financial Services Co. MA Increases Stock Position in Colgate-Palmolive Company $CL

Massachusetts Financial Services Co. MA has increased its stake in Colgate-Palmolive Company (NYSE:CL) by 1.3% in the second quarter, bringing its total holdings to 4.77 million shares valued at approximately $458.7 million. Institutional investors collectively own 80.41% of the company, and analysts generally maintain …

Molson Coors’s Q2 Earnings Call: Our Top 5 Analyst Questions

Molson Coors's Q2 Earnings Call: Our Top 5 Analyst Questions Molson Coors' Q2 results were shaped by external pressures that weighed on sales and profitability, with revenue meeting Wall Street's expectations but operating margin declining significantly from the prior year. Management attributed the performance …

GUARDCAP ASSET MANAGEMENT Ltd Has $118.33 Million Stake in Colgate-Palmolive Company $CL

GUARDCAP ASSET MANAGEMENT Ltd significantly reduced its stake in Colgate-Palmolive Company (NYSE:CL) by 18.1% in the second quarter, although it still holds 1.30 million shares valued at $118.3 million, making it 8.4% of its portfolio. Analysts have a "Moderate Buy" consensus for Colgate-Palmolive with …

Colgate-Palmolive Co at Deutsche Bank dbAccess Global Consumer Conference Transcript

This article provides a transcript from Colgate-Palmolive Co's presentation at the Deutsche Bank dbAccess Global Consumer Conference held on June 3, 2026. The discussion highlights the company's use of AI to accelerate the deployment of marketing communications globally. It also touches upon structural and …

Moleculin Biotech Releases Q2 2026 Financial Results

Moleculin Biotech (MBRX) reported a net loss of $7.6 million for Q2 2026, with a significant improvement in loss per share, narrowing to $1.40 from $12.25 in Q2 2025. The company, focused on therapeutic candidates for tumors and viruses, generated no revenue but continued …

H.C. Wainwright reiterates Buy on 4D Molecular stock, $36 target By Investing.com

H.C. Wainwright has reiterated a Buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT) with a $36.00 price target, citing positive two-year data from the Phase 2b PRISM trial for its 4D-150 gene therapy. The company has also completed enrollment for its pivotal Phase 3 4FRONT-2 …

Molina Healthcare Inc (MOH) Stock Up 3.3% and Still Undervalued -- GF Score: 76/100

Molina Healthcare Inc (MOH) shares recently rose 3.3%, bringing its current price to $212.43. Despite a GF Value™ of $381.21 indicating a 44.3% undervaluation, caution is advised due to the company being cash-flow-negative. The GF Score™ of 76/100 reflects a robust financial position in …

Moleculin Biotech (NASDAQ: MBRX) seeks reverse split and plan changes at 2026 meeting

Moleculin Biotech (NASDAQ: MBRX) is holding its 2026 annual shareholder meeting on October 9, 2026, where key proposals include electing directors, ratifying the independent auditor, and approving an amendment to the 2024 Equity Incentive Plan to increase authorized shares. Shareholders will also vote on …

Molina Healthcare Inc. stock outperforms competitors on strong trading day

Molina Healthcare Inc. (MOH) stock rose by 3.27% to $212.43 on a generally down day for the market, outperforming both the S&P 500 and Dow Jones Industrial Average. The company's stock closed 13.25% below its 52-week high achieved in July.

Meghmani Organics files FY26 BRSR report with 42% renewable energy share

Moleculin Biotech GAAP EPS of -$1.40 misses by $0.53

* Moleculin Biotech press release [https://seekingalpha.com/pr/20619725-moleculin-biotech-reports-second-quarter-2026-financial-results-and-highlights-continued] (MBRX [https://seekingalpha.com/symbol/MBRX]): Q2 GAAP EPS of -$1.40 misses by $0.53. * As of June 30, 2026, the company had cash and cash equivalents of approximately $7.3 million. Management believes that its cash on hand and cash equivalents as …

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial

Moleculin Biotech reported its second-quarter 2026 financial results, highlighting significant progress in its pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed or refractory AML. Positive interim data showed complete remission rates three times higher than the control group, with enrollment on track for …

Meghmani Organics FY26 Results: Net profit rises 89% YoY to ₹125.3 crore

Meghmani Organics Share Price Gains; Price, Valuation View

Shandong Molong Sets Late-August Board Meeting to Review Interim Results and Dividend

Here’s How Much You Would Have Made Owning Molina Healthcare Stock In The Last 15 Years

Molina Healthcare (NYSE: MOH) has outperformed the market over the past 15 years, achieving an average annual return of 17.74%. An investment of $1000 in MOH stock 15 years ago would now be worth $11,447.41, demonstrating the significant impact of compounded returns on cash …

Colgate® Launches New Optic White™ Vitamin C with j-hope of BTS

Colgate-Palmolive has launched a new whitening toothpaste, Colgate Optic White Vitamin C, featuring 95% pure stabilized Vitamin C. The company announced a major Asia Pacific partnership with j-hope of BTS, known for his "Sunshine Smile," as the official ambassador. The product claims to remove …

Can Molson Coors Beverage (TAP) Stay Undervalued As Operational Headwinds Pressure Shipments?

Molson Coors Beverage (TAP) is facing operational challenges, including brewery downtime and glass supply constraints, leading to an expected 6% to 9% decline in U.S. shipments. Despite these issues, the stock is considered 9.7% undervalued with a fair value of $46.00, driven by its …

Is Weaker Q2 Earnings Amid Buybacks Altering The Investment Case For Molson Coors (TAP)?

Is 4D Molecular Therapeutics Inc (FDMT) Undervalued After Q2 Ear

4D Molecular Therapeutics (NASDAQ:FDMT) Announces Quarterly Earnings Results

Moleculin Biotech (NASDAQ: MBRX) advances AML trial but warns on cash

Moleculin Biotech (NASDAQ: MBRX) is progressing with its pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed/refractory AML, showing promising preliminary efficacy and cardiac safety data. Despite these clinical advancements and a recent $9.3 million equity/warrant offering, the company reported a net loss of …